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Received 24 June 2003; revised 4 February 2004; accepted 13 February 2004Aim Little is known about the prognostic significance of silent versus symptomatic
coronary artery disease (CAD) in diabetic patients. We therefore assessed the
incidence of scintigraphic evidence of CAD in diabetic patients without known CAD
and the impact of symptoms and scintigraphic findings on prognosis.
Methods and results A consecutive series of 1737 diabetic patients without known
CAD underwent dual-isotope myocardial perfusion SPECT (MPS) and 1430 were fol-
lowed-up for a median of 2 (1–8.5) years. Critical events were defined as myocardial
infarction or cardiac death.
Objective evidence of CAD was found in 39% of 826 asymptomatic diabetic pa-
tients, in 51% of 151 diabetic patients with shortness of breath (SOB), and in 44% of
760 diabetic patients with angina. During follow-up, 98 critical events occurred.
Annual critical event rates were 2.2% in asymptomatic, 3.2% in angina, and 7.7% in
diabetic patients with shortness of breath (p < 0:001 versus other groups). With MPS
evidence of CAD, critical event rates increased to 3.4% (asymptomatic), 5.6% (an-
gina), and 13.2% (SOB) (p6 0:009 versus no evidence of CAD). Age, hypertension,
shortness of breath, scarring and ischaemia were independent predictors of critical
events. MPS findings added incremental information to prescan information regarding
outcome prediction.
Conclusions In asymptomatic diabetic patients, the rate of objective evidence of CAD
and annual critical events were similar to those found in diabetic patients with an-
gina. The outcome was three times worse in diabetic patients with shortness of
breath. MPS findings were strongly predictive of outcome and proved valuable for risk
stratification.c 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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The prevalence of type II diabetes is increasing rapidly
in Western nations due to the aging of the population,
increased frequency of obesity, and suboptimal nutri-
tional habits.1;2 Type II diabetes is associated with a
substantially elevated risk of cardiovascular morbidity
and mortality. This adds to the prospect that an “epi-
epidemic” of coronary artery disease (CAD) will appear
over the coming decades. Atherosclerosis accounts for
65–80% of all deaths among diabetic patients, com-
pared with one-third of all deaths in the general pop-
ulation.3 The cardiovascular mortality rate is more than
twice as high in diabetic men and more than fourfold
greater in diabetic women, compared with their non-
diabetic counterparts.4 When advanced CAD is detected
in diabetics, coronary artery bypass surgery has been
shown to improve survival and may be superior to per-
cutaneous coronary interventions, probably due in part
to the presence of more diffuse CAD in diabetic pa-
tients.5 However, due to the high prevalence of silent
CAD in diabetics,6–10 up to 65%, the detection of CAD
deserving intervention is crucial.
Myocardial perfusion SPECT (MPS) is widely used in the
risk stratification of patients with known or suspected
CAD.11–19 However, little is known about the interrela-
tionship of symptoms and MPS findings in diabetic pa-
tients. Clinically, this is particularly important since
symptoms in diabetic patients are more often absent or
atypical (shortness of breath) than in nondiabetic pa-
tients.8;20;21 The aim of the present study was therefore
twofold: (1) to assess the incidence of MPS evidence of
CAD in a diabetic patient cohort without known CAD, (2)
to evaluate the impact of patient symptoms and MPS
findings on prognosis in such diabetic patients.Methods
Study population
A large consecutive cohort of 2943 diabetic patients referred for
CAD evaluation were tested by exercise or adenosine stress MPS
between February 1991 and May 1998. The diagnosis of diabetes
mellitus was based on a known history of glucose intolerance
and/or antidiabetic drug therapy at the time of stress testing,
but no details were recorded in the case report form. Patients
with a history of CAD (history of myocardial infarction or re-
vascularisation) were excluded, leaving 1737 patients (59% of
the initial cohort) as the diagnostic study population. Of these,
760 (44%) had chronic chest pain (angina pectoris or angina-like
pain) and served as the control group, whereas 977 patients
(56%) had either shortness of breath (SOB; n ¼ 151) only or nospecific cardiac complaints (n ¼ 826). The median follow-up
time for these patients was 2 years (all >1 year, range 1–8.5
years, interquartile range 1.6–2.6 years). Not included in this
follow-up evaluation were 161 patients who underwent revas-
cularisation as a direct consequence of the MPS findings (<60
days after MPS)22;23 and 146 patients who were lost to follow-up
(8%), leaving a prognostic study population of 1430 patients.
Imaging and stress protocol
All patients underwent rest Tl-201/stress Tc-99m sestamibi MPS,
as previously described.24 Patients were injected intravenously
at rest with Tl-201 (2.5–3.5 mCi), with the dose adjusted for
patient weight. Rest Tl-201 SPECT was initiated 10 min after
injection of the radionuclide.
Exercise MPS protocol
Immediately following imaging, patients performed a symptom-
limited treadmill exercise test using standard protocols, with
12-lead electrocardiographic recording each minute of exercise
and continuous monitoring of leads AVF, V1, and V5. Exercise
endpoints included physical exhaustion, severe angina, sus-
tained ventricular tachycardia, haemodynamically significant
supraventricular arrhythmias, or exertional hypotension. At near
maximal stress, a 20–30 mCi dose of Tc-99m sestamibi was in-
jected (the actual patient dose was adjusted for patient weight)
and exercise continued for 1 additional minute after injection.
Tc-99m sestamibi SPECT imaging was begun 15–30 min later.24
Adenosine MPS protocol
Patients were instructed not to consume caffeine-containing
products for 24 h before MPS. Following rest Tl-201 SPECT,
pharmacologic stress was performed using adenosine infusion
(140 lg/kg/min for 5–6 min). Tc-99m sestamibi (20–30 mCi)
was injected at the end of the 2–3 min of infusion and SPECT
was initiated 60 min after the end of adenosine infusion.24 For
patients who underwent exercise as an adjunct to adenosine
infusion, low-level treadmill exercise was performed at 0% and
1–1.7 mph.
During both types of stress, blood pressure was measured and
recorded at rest, at the end of each exercise stage, and at peak
exercise. Maximal ST-segment change at 80 ms after the J point
was assessed as horizontal, upsloping, or downsloping.
SPECT acquisition protocol
SPECT was performed as previously described using circular or
elliptical 180 acquisition for 64 projections, 20 s per projec-
tion.24 During imaging, two energy windows for Tl-201 were
utilised (30% window centred on the 68–80 keV peak and a 10%
window centred on the 167 keV peak) and a 15% window centred
on the 140 keV peak was used for Tc-99m sestamibi. No atten-
uation or scatter correction was used.
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Semiquantitative visual interpretation was performed using a
20-segment model as previously described.25 Each segment was
scored using a 5-point scoring system (0¼normal, 1¼equivocal,
2¼moderate, 3¼ severe reduction of radioisotope uptake, and
4¼ apparent absence of detectable tracer uptake in a segment).
A summed stress score (SSS) was obtained by adding the scores
of the 20 segments of the stress images.24 A summed rest score
(SRS ¼ extent of scar) was obtained in a similar way by adding
the scores of the 20 segments on the rest images. Subsequently,
to assess the extent of ischaemia, a summed difference score
(SDS ¼ extent of ischaemia) was calculated by subtracting the
SRS from the SSS. The number of nonreversible segments (NRS)
(stress-rest score combinations of 4–4, 4–3, 3–3, 3–2, or 2–2)
was used as a surrogate marker of left ventricular ejection
fraction (with each NRS representing approximately 5% of the
myocardium), since ejection fraction data from gated SPECT
were not available for the entire patient population.
As per our previous work, SSS <4 was considered normal;
4–8, mildly abnormal; 9–13 moderately abnormal, and >13
severely abnormal.13 Similarly, patients with SDS <2 and P 2
were considered nonischaemic and ischaemic, respectively.
Patient follow-up
Individuals who were unaware of the patients’ test results per-
formed follow-up using scripted telephone interviews. The
endpoint of interest was hard events: myocardial infarction or
cardiac death. Cardiac death was defined as death due to any
cardiovascular cause and was confirmed by review of the death
certificate, hospital chart, or physician’s record; nonfatal my-
ocardial infarction was documented by a consistent history ac-
companied by elevation of cardiac enzymes and/or new Q waves
on the ECG.11;25Statistical analysis
Comparisons between patient groups were performed using one-
way ANOVA (followed by the Bonferroni test) for continuous
variables and a v2 test for the categorical variables. When the
categorical variables of three patient groups were compared,
the groups were tested pairwise, followed by the Bonferroni
test. All continuous variables are described as means SD. A p
value <0.05 was considered statistically significant.
Predicted event rates were determined using each patient’s
hazard scores from the final Cox proportional hazards model.
These event rates were annualised by dividing them by the mean
follow-up time. Kaplan–Meier cumulative event-free survival
curves were used to compare the survival of different patient
groups (log-rank test).
Regarding prognosis, univariate predictors of critical events
were evaluated by a Cox proportional hazards model. The as-
sociation between relevant variables and risk of adverse out-
comes was determined using a multivariate Cox proportional
hazards model. The selection of the variables entered in the
model was based on univariate significance (age, hypertension,
shortness of breath, stress modality, SRS, SDS), and reported
prognostic indicators such as sex, hypercholesterolaemia,
smoking, family history of CAD, angina, angina during stress
testing, and ECG response during stress testing. A forward
stepwise method was then applied using a p value <0.10 for
inclusion and >0.20 for exclusion into the model.Since the patient population that had a left ventricular
ejection fraction available was too small to run a separate
analysis with the endpoint of critical event, a separate model
was built incorporating NRS instead of SRS (all other covariates
unchanged).
The incremental value of nuclear testing was determined by
calculating the change in global v2 after adding the nuclear
variables (SRS, SDS) to the prescan information (age, sex,
shortness of breath, angina, hypertension, hypercholesterola-
emia, smoking, family history of CAD, stress modality, angina
during stress testing, and ischaemic ECG during stress testing)
with respect to prognosis (Cox model). Analyses were made
using SPSS statistical package (version 11.5).Results
Baseline characteristics in relation to symptoms
Of 1737 diabetic patients referred for evaluation of CAD,
826 (47%) were asymptomatic and 151 (9%) had shortness
of breath. The characteristics of these patients in rela-
tion to the control group of 760 patients with chronic
angina (44%) are shown in Table 1. Asymptomatic pa-
tients were more likely to be male, had a family history
of CAD less often, and had a lower extent of ischaemia
(SDS) than symptomatic patients and differed from pa-
tients with shortness of breath in lower age, smaller
percentage of female patients, higher frequency of ex-
ercise treadmill testing and ischaemic ECG changes, and
lower overall abnormality of MPS findings (SSS), scarring
(SRS) and extent of ischaemia (SDS) (Table 1). Patients
with shortness of breath were older than the other two
patient groups, more often had evidence of scarring and
larger scars (SRS, NRS) than asymptomatic patients and
patients with angina, a higher rate of scarring and is-
chaemia with more overall abnormality of MPS findings
(SSS) and only slightly greater extent of ischaemia (SDS)
(Table 1). In addition, patients with shortness of breath
could perform an exercise treadmill test less often and
had ischaemic ECG changes less often (Table 1).
Patients with shortness of breath had a higher number
of nonreversible segments compared to the other two
patient groups (Table 1). Together with the lower left
ventricular ejection fraction observed in a subgroup
analysis of 388 patients (27%) for which this data was
available (patients with shortness of breath had a sig-
nificantly lower ejection fraction [52 19%, p6 0:025
versus the other two groups] than asymptomatic patients
[58 14%] and patients with angina [60 13%]), this
points to a higher rate of silent prior myocardial infarc-
tion in patients with shortness of breath.
Of note, the overall MPS abnormality, expressed as
SSS, was not significantly different between patients
with (6.0 8.5) and without angina (5.5 7.7).MPS evidence of CAD in relation to symptoms
Overall, 730 (42%) patients had abnormal MPS results.
There were no significant differences between the
asymptomatic group (39%) and patients with angina
Table 1 Patient characteristics by symptomatic status
All patients (n ¼ 1737) Asymptomatic (n ¼ 826) SOB (n ¼ 151) Angina (n ¼ 760)
Age (years) 65.8 11.5 65.0 11.6y 71.5 10.1 65.4 11.3#
Female sex, n (%) 848 (49) 351 (43) ;y 81 (54) 416 (55)
Hypercholesterolaemia, n (%) 824 (47) 374 (45) 64 (42) 386 (51)
Smoker, n (%) 216 (12) 93 (11) 23 (15) 100 (13)
Hypertension, n (%) 1140 (66) 520 (63) 105 (70) 515 (68)
Family history of CAD, n (%) 357 (21) 140 (17) 32 (21) 185 (24)
Exercise treadmill test, n (%) 893 (51) 443 (54)y 48 (32) 402 (53)#
Ischaemic ECG, n (%) 270 (16) 127 (15)y 9 (6) 134 (18)#
SSS 5.8 8.4 5.0 7.7y 8.8 11.0 6.0 8.5#
SRS 1.2 4.0 1.1 3.8y 3.3 7.1 0.9 3.2#
SDS 4.6 7.0 3.9 6.4,y 5.5 8.0 5.1 7.5
NRS 0.5 1.5 0.4 1.4y 1.3 2.6 0.4 1.3#
Pts with normal MPS, n (%) 1007 (58) 504 (61)y 74 (49) 429 (56)
Pts with scarring, n (%) 66 (4) 36 (4) 10 (7) 20 (3)#
Pts with ischaemia, n (%) 465 (27) 203 (25) 31 (20) 231 (30)#
Pts with scarring plus ischaemia, n (%) 199 (11) 83 (10)y 36 (24) 80 (11)#
SOB, shortness of breath; SSS, summed stress score (overall abnormality of MPS); SRS, summed rest score (scarring); SDS, summed difference score
(extent of ischemia); NRS, number of nonreversible segments.
# Significant difference between patients with angina and patients with shortness of breath (significant difference: p < 0:02).
 Significant difference between asymptomatic patients and patients with shortness of breath (significant difference: p < 0:02).
* Significant difference between asymptomatic patients and patients with angina (significant difference: p < 0:02).
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in patients with shortness of breath (51%), being
significantly higher than in asymptomatic patients (39%,
p ¼ 0:006), probably because more patients with short-
ness of breath had evidence of scarring (prior silent
myocardial infarction) with or without ischaemia com-
pared to the other two groups (Table 1). Thus, in the
low-risk group of diabetic patients tested, more than
one-third had MPS evidence of CAD, irrespective of
symptomatic status.
It is noteworthy that the 307 patients excluded from
the prognostic part of the study had ischaemic ECG
changes during stress testing more often, a higher overall
abnormality of MPS findings (SSS), more extensive scar-
ring (SRS), and more extensive ischaemia (SDS) than the
prognostic study population (n ¼ 1430) (data not shown).
This is consistent with the fact that 161 of these patients
underwent early revascularisation.Outcome events and event prediction
During a median follow-up of 2 years (range 1–8.5
years), 98 critical events occurred in the prognostic pa-
tient population of 1430 patients, which is consistent
with an annual event rate of 3.1%: 65% were nonfatal
myocardial infarctions and 35%, cardiac deaths. Annual
event rates were similar in females and males, 3.3% and
2.9%, respectively (p ¼ 0:66). Asymptomatic patients,
patients with angina, and patients with shortness of
breath had annual critical event rates of 2.2%, 3.2%, and
7.7%, respectively. Patients with shortness of breath had
significantly more events than asymptomatic patients
(p < 0:0001) and patients with angina (p ¼ 0:0002),
whereas the difference between asymptomatic patientsand patients with angina was statistically nonsignificant
(p ¼ 0:44).
Event-free survival as a function of MPS results
Overall, patients with normal MPS results had a signifi-
cantly lower annual critical event rate than patients with
abnormal MPS results, 1.9% and 5.4%, respectively
(p < 0:0001); this held true for all three patient groups
(Fig. 1). In patients with normal MPS results, annual
critical event rates were not significantly different when
asymptomatic patients, patients with angina, and pa-
tients with shortness of breath were compared. In con-
trast, in patients with abnormal MPS findings, patients
with shortness of breath had significantly higher annual
critical event rates than asymptomatic patients
(p < 0:0001) and patients with angina (p ¼ 0:0008),
whereas asymptomatic patients and patients with angina
had a similar outcome (p ¼ 0:33). The cumulative event-
free survival of patients with abnormal MPS results is
shown in Fig. 2. Annual event rates of patients with
normal MPS findings and evidence of scarring, of is-
chaemia, and of scarring plus ischaemia are shown in
Table 2. Annual event rates were lowest in patients with
normal MPS results and highest in patients with evidence
of scarring plus ischaemia.Univariate and multivariate predictors of critical
events
Univariate predictors of critical events are summarised in
Table 3. Age, hypertension, shortness of breath, phar-
Fig. 1 Annual event rates as a function of MPS results and symptomatic
status (n ¼ 1430). Pts, patients; MPS, myocardial perfusion SPECT.
Table 3 Univariate predictors of critical events
Hazard ratio v2 95% confidence interval p
Lower Upper
Age 1.05 22.1 1.03 1.07 <0.0001
Female sex 0.9 0.2 0.6 1.4 0.66
Hypertension 1.6 4.3 1.03 2.59 0.04
Smoking 1.1 0.03 0.6 1.9 0.87
Hypercholesterolaemia 1.3 1.9 0.9 2.0 0.17
Family history of CAD 1.3 1.1 0.8 2.0 0.29
Angina 1.1 0.3 0.7 1.7 0.59
Shortness of breath 2.9 18.5 1.8 4.7 <0.0001
Pharmacologic stress 2.1 11.5 1.4 3.2 0.001
Angina during stress 1.1 0.1 0.5 2.5 0.74
ECG ischaemic during test 1.2 0.4 0.7 2.1 0.52
SSS 1.07 51.1 1.05 1.09 <0.0001
SRS 1.07 21.9 1.04 1.1 <0.0001
SDS 1.07 34.1 1.04 1.09 <0.0001
NRS 1.19 19.4 1.10 1.28 <0.0001
CE, critical event (myocardial infarction or cardiac death); SSS, summed stress score; SRS, summed rest score; SDS, summed difference score; NRS,
number of nonreversible segments.
Fig. 2 Kaplan–Meier event-free survival curves as a function of symp-
toms in patients with abnormal MPS. Asymptomatic patients and patients
with angina had a significantly better survival than patients with SOB
(p < 0:001), (n ¼ 1430). Pts, patients; SOB, shortness of breath.
Table 2 Annual critical events rate as a function of MPS results and symptoms
All patients (n ¼ 1430) Asymptomatic (n ¼ 701) SOB (n ¼ 124) Angina (n ¼ 605)
Pts with normal MPS 1.9% 1.6% 3.3% 2.0%
Pts with scarring 4.1% 4.7% 5.1% 2.7%
Pts with ischaemia 4.6% 2.9%y 13.6% 5.2%#
Pts with scarring plus ischaemia 7.6% 4.0%y 15.7% 7.6%
# Significant difference between patients with angina and patients with shortness of breath (significant difference: p < 0:02).
 Significant difference between asymptomatic patients and patients with shortness of breath (significant difference: p < 0:02).
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univariate predictors of critical events.
In the multivariate Cox proportional hazards model,
age, hypertension, shortness of breath, extent of scarring
(SRS), and extent of ischaemia (SDS) were independent
predictors of events (Table 4). Hypercholesterolaemia
and family history of CAD tended to be independentpredictors of events. Of note, angina was not a significant
predictor of critical events in this model, but shortness of
breath was. In addition, a separate analysis was run in
which the NRS was used as a surrogate marker for ejection
fraction. NRS turned out to be a highly significant inde-
pendent predictor of critical events (HR 1.16, 95% CI
1.06–1.26; p ¼ 0:003).
Table 4 Results of the Cox proportional hazard’s model for the prediction of critical events
Hazard ratio v2 95% confidence interval p
Lower Upper
Age 1.04 16.8 1.02 1.07 <0.0001
Hypercholesterolaemia 1.5 3.4 0.98 2.3 0.07
Family history of CAD 1.6 3.5 0.98 2.5 0.06
Hypertension 1.83 6.4 1.14 2.92 0.012
Shortness of breath 2.1 7.8 1.24 3.42 0.005
SRS 1.06 13.6 1.03 1.09 <0.0001
SDS 1.07 32.8 1.04 1.09 <0.0001
CE, critical event (myocardial infarction or cardiac death); SRS, summed rest score; SDS, summed difference score.
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served. The presence of hypertension increased risk by
83%. Shortness of breath more than doubled risk. An in-
crease of 10 points in SRS or SDS increased risk by 60%
and 70%, respectively.
After adjusting for historical and stress test data ob-
tained before MPS, both scarring (SRS) and extent of is-
chaemia (SDS) remained significant predictors of critical
events, thus yielding incremental value over prescan
data. The incremental value of nuclear testing was re-
flected by a significant increase of global v2 from 52 to 98
(p < 0:0001).Discussion
This study of a large, consecutive series of diabetic pa-
tients referred for evaluation of possible or suspected
CAD showed that silent CAD, as diagnosed by MPS, was
found in 39% of patients. The rate of abnormal MPS results
did not differ from that of patients with angina or angina-
like chest pain, in contrast to nondiabetic patients.26
However, patients presenting with shortness of breath
had a significantly higher rate of abnormal MPS results
(higher incidence of CAD) than the other two groups. This
finding underscores the fact that absence of angina is not
equivalent to absence of CAD in diabetic patients.
If the study population was compared to a patient
population with known CAD and stable angina, as in the
Impact Of Nicorandil in Angina randomised trial (IONA),27
the diabetic patients of the present study without MPS
evidence of CAD had an outcome similar to that of IONA
study patients, with annual critical event rates of 1.9%
and 2.9%, respectively (p ¼ 0:44). In contrast, the dia-
betic patients of the present study with MPS evidence of
CAD had a significantly worse outcome than IONA study
patients, with critical event rates of 5.4% and 2.9%, re-
spectively (p < 0:0001).
In the present study, in patients with normal MPS (no
evidence of CAD) outcome did not differ in the three
patient groups (asymptomatic patients, patients with
angina, and patients with SOB). Furthermore, outcome
was very similar in diabetic patients with MPS evidence
of CAD, irrespective of the presence of chest pain.
However, the outcome was significantly worse in pa-
tients with shortness of breath as their presentingsymptom. Most likely this was due to the fact that these
patients had MPS evidence of more prior silent myocar-
dial infarctions and therefore had a significantly lower
left ventricular ejection fraction than asymptomatic
patients and patients with angina.
Age, hypertension, shortness of breath, and MPS
variables of scarring and ischaemia were independent
predictors of outcome. In addition, MPS provided incre-
mental value to clinical and prescan variables to predict
outcome in this relatively low-risk diabetic population.
Incidence of silent CAD in diabetic patients
In several studies evaluating the incidence of silent is-
chaemia in diabetic patients, the rate was as high as 65%
and increased in various clinical settings and in the
presence of risk factors. Higher rates were observed in
patients older than 60 years28 and in patients with sev-
eral risk factors, such as concomitant peripheral arterial
vascular disease,7 retinopathy,6 microalbuminuria,10;29
and autonomic neuropathy.30
In a population-based autopsy study of decedents
without clinical CAD, diabetes was associated with a
global coronary artery disease burden and a prevalence
of high-grade atherosclerosis similar to that observed
among nondiabetic subjects with clinical CAD.31 Diabetic
decedents (mean age 75 11 years) and their nondia-
betic counterparts (mean age 73 15 years) had high-
grade atherosclerosis in 68% and 46%, respectively.31
Wackers et al.32 recently reported the preliminary re-
sults of the Detection of Ischaemia in Asymptomatic Di-
abetics (DIAD) trial, the first large prospective trial
evaluating silent CAD in diabetic patients. In a low-risk
diabetic population (e.g., patients with ECG abnormali-
ties consistent with CAD were not enrolled into the DIAD
study), 27% of patients had evidence of abnormal MPS.
These rates of silent CAD are lower than in the present
study, where a higher risk group and older diabetic pa-
tients were studied.
Impact of symptoms and silent CAD on prognosis
in diabetic patients
Several studies have shown that in the presence of my-
ocardial ischaemia, diabetic patients report angina less
frequently than nondiabetic patients20;33 and shortness
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present study, only 45% of diabetic patients with MPS
evidence of CAD had chest pain whereas 11% reported
shortness of breath as the only symptom. In addition, the
present findings show that outcome was related much
more to the presence or absence of ischaemia and
scarring than to symptoms: annual event rates were
similar in patients with or without angina, whereas they
were higher in diabetic patients presenting with short-
ness of breath. Thus, this symptom in diabetic patients
seems to be related primarily to prior silent infarctions
and not to ischaemia alone and should therefore be
carefully considered in these patients.
There is only limited prognostic data of diabetic pa-
tients with silent ischaemia. In a relatively small patient
population, Weiner et al. demonstrated that in the
presence of exercise-induced myocardial ischaemia
(whether silent or symptomatic), long-term survival was
worse in diabetics than in nondiabetics. In contrast, in
the absence of ischaemia, the mortality risk was not in-
creased for diabetic patients. Importantly, survival rates
among patients with silent ischaemia were similar to
those of symptomatic patients regardless of diabetic
status.33 In a scintigraphic study, diabetic patients with
normal, mildly abnormal, and moderately to severely
abnormal MPS results, assessed by the overall abnor-
mality of MPS findings (SSS), had relatively low (1–2% per
year), intermediate (3–4% per year), and high hard event
rates (>7% per year; p < 0:001), respectively.35 These
findings were confirmed by Giri et al.,36 who compared
MPS results of diabetic versus nondiabetic patients with
respect to prognosis. The presence and extent of ab-
normal MPS findings independently predicted subsequent
cardiac events. Diabetic women had the worst outcome
for any given extent of myocardial ischaemia. These re-
sults indicate that myocardial perfusion SPECT provides
important incremental prognostic information in the
evaluation of diabetic patients. The present study ex-
tends these observations to a large group of diabetic
patients with a relatively low risk for CAD. Still, the ob-
served event rates in asymptomatic patients were com-
parable to those of patients with angina, which
underscores the relevance of silent CAD in diabetic pa-
tients and, hence, the importance of detecting silent
CAD by MPS.
Special aspects of the present study
Besides objective evidence of ischaemia, scarring, and
age, this study identified hypertension as an independent
predictor of outcome in patients with diabetes. This is
consistent with previous trials that demonstrated the
outstanding importance of tight blood pressure control in
diabetic patients.37–40 The hazard ratio in our Cox model
indicated that the presence of hypertension had a similar
impact on outcome, as a 12% or 14% increase in the ex-
tent of ischaemia or scarring, respectively. In addition,
the present study underscores the importance of risk-
stratifying asymptomatic diabetic patients as
recommended by the American Diabetes Association for
high-risk patient subgroups.41 However, these recom-mendations were based on the clinical judgment of a
panel of experts rather than on published data.42 Our
study adds evidence to these recommendations and
suggests a role for cardiac imaging in diabetic patients.
Finally, results of noninvasive testing may become rele-
vant for treatment decisions, although specific trials in
diabetic patients are lacking. Still, the findings of The
Asymptomatic Cardiac Ischemia Pilot Study (ACIP)
showed that in patients with silent ischaemia, revascu-
larisation significantly reduced death, myocardial in-
farction, and cardiac hospitalisation compared to such
patients managed conservatively.43Limitations
Regarding the incidence of silent ischaemia in diabetic
patients, there is a certain bias in our patient population
because patients were referred for testing based on
clinical circumstances. There is also no detailed infor-
mation about the type and duration of diabetes, mode of
treatment, or degree of diabetic control, and only in-
sufficient information was available about secondary
organ involvement and autonomic nerval dysfunction,
variables that have been shown to be associated with a
higher rate of CAD in diabetic patients. However, the
present study focused on symptomatic presentation in
diabetic patients and its relation to MPS findings and
outcome rather than on degree of diabetes control.Conclusions
In an asymptomatic, diabetic patient population re-
ferred for evaluation of CAD, the frequency of scinti-
graphic evidence of CAD was 39%, as high as in patients
with angina. Accordingly, the annual critical event rate
was similarly and strongly dependent on objective evi-
dence of CAD. The proportion of patients with MPS ev-
idence of CAD was significantly higher in patients
presenting with shortness of breath and outcome was
more than three times worse, most likely due to prior
silent infarctions, as shown by larger areas of scarring
and a worse left ventricular ejection fraction. Age and
hypertension were other independent predictors of
events. MPS added incremental information to clinical
and prescan information to predict outcome, indicating
that MPS seems to be valuable for risk stratification of
asymptomatic diabetic patients with respect to the di-
agnosis of CAD and its prognosis.References
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